09/18/23 4:16 PMNasdaq : SXTP, SXTPW clinical trialcovid-19low float60 Degrees Pharma Withdraws COVID Phase IIB IND, Will Resubmit Pending Assessment of Ability to Meet FDA RequirementsPrompted by advice from FDA regarding study design, 60P Australia Pty Ltd, a majority-owned subsidiary of 60 Degrees Pharmaceuticals, has withdrawn its IND for ACLR8-LR, a Phase IIB study of the use of tafenoquine in treating COVID-19; Company plans to resubmit a revised IND later in 2023, pendingRHEA-AIneutral
09/06/23 7:31 AMNasdaq : SXTP, SXTPW conferenceslow float60 Degrees Pharmaceuticals to Participate in H.C. Wainwright 25th Annual Global Investment Conference60 Degrees Pharmaceuticals Inc. (“60P” or the “Company”) (Nasdaq: SXTP ), a pharmaceutical companyRHEA-AIneutral
09/01/23 9:00 AMNasdaq : GENE, SXTP low floatGenetic Technologies Limited and 60 Degrees Pharmaceuticals Interviews to Air on the RedChip Money Report(R) on Bloomberg TVORLANDO, FL / ACCESSWIRE / September 1, 2023 / RedChip Companies will air interviews with Genetic Technologies Limited (Nasdaq:GENE) and 60 Degrees Pharmaceuticals (NASDAQ:SXTP) on The RedChip Money Report®, a sponsored program on Bloomberg TV, this Saturday, September 2, at 7 p.m. EasternRHEA-AIneutral
08/30/23 7:32 AMNasdaq : SXTP, SXTPW low float60 Degrees Pharmaceuticals Study Results Published by New Microbes and New Infections Demonstrate Tafenoquine Exhibits Broad Spectrum Antifungal ActivityData showed tafenoquine does not exhibit cross-susceptibility with fluconazole against Candida spp. Effective treatment of drug-resistant Candida infections is an unmet need in U.S. market Presumed mode of action differentiated from standard of care treatment WASHINGTON, Aug. 30, 2023 (GLOBERHEA-AInegative
08/22/23 7:31 AMNasdaq : SXTP, SXTPW low float60 Degrees Pharmaceuticals Receives Additional U.S. Patent Covering Tafenoquine for Prevention of Plasmodium Falciparum Malaria60P was awarded additional U.S. patent protection to further solidify its exclusive rights through 2035 for tafenoquine for prevention of Plasmodium falciparum malaria in naïve individuals Tafenoquine kills dormant liver stage of P. vivax parasite and clears the blood stages of P. falciparumRHEA-AIneutral
08/15/23 7:31 AMNasdaq : SXTP, SXTPW clinical trialcovid-19low float60 Degrees Pharmaceuticals Registers ACLR8-LR, a Phase IIB Study of Tafenoquine for Treatment of COVID-19, on ClinicalTrials.gov ACLR8-LR, a double-blind, randomized, placebo-controlled Phase IIB study to determine efficacy of the ARAKODA ® regimen of tafenoquine in COVID-19 patients with mild-moderate symptoms and low risk of disease progression, has been registered on ClinicalTrials.gov 60P’s majority-owned subsidiary, 60PRHEA-AIneutral
07/31/23 7:59 AMNasdaq : SXTP, SXTPW low float60 Degrees Pharmaceuticals Awarded Canadian Patent Covering Tafenoquine for Prevention of Malaria in Malaria-Naive SubjectsPatent provides exclusive use of tafenoquine for prevention of malaria in malaria-naive individuals in Canada until late 2035. Tafenoquine is the active molecule in 60 Degrees Pharmaceuticals’ USFDA-approved drug for malaria prevention, ARAKODA ®. Most travelers from Canada and the United States toRHEA-AIneutral
07/21/23 9:00 AMNasdaq : SXTP, UNCY low float60 Degrees Pharmaceuticals and Unicycive Therapeutics Interviews to Air on Bloomberg TV on the RedChip Money Report(R)ORLANDO, FL / ACCESSWIRE / July 21, 2023 / RedChip Companies will air interviews with 60 Degrees Pharmaceuticals, Inc. (NASDAQ:SXTP) and Unicycive Therapeutics, Inc. (NASDAQ:UNCY) on The RedChip Money Report® on Bloomberg TV, this Saturday, July 22, at 7 p.m. Eastern Time (ET). Bloomberg TV isRHEA-AIneutral
07/14/23 1:30 PMNasdaq : SXTP, SXTPW low floatWallachBeth Capital Announce Closing Of 60 Degrees Pharmaceuticals IPO At $5.30 Per UnitWallachBeth Capital LLC, a leading provider of capital markets and institutional execution services, announced today that 60 Degrees Pharmaceuticals, Inc., specialists in developing and marketing medicines for infectious diseases has completed its previously announced IPO of 1,415,095 units at a price of $5.30...RHEA-AIneutral
07/14/23 12:39 PMNasdaq : SXTP, SXTPW IPOofferinglow float60 Degrees Pharmaceuticals Announces Closing of Initial Public Offering60 Degrees Pharmaceuticals , Inc., (NASDAQ: SXTP; SXTPW) (“60P” or the “Company”), specialists in developing and marketing medicines for infectious diseases, announced today the closing of its initial public offering of 1,415,095 units (each, aRHEA-AIneutral
